Crescent Biopharma (CBIO) vs REGENXBIO (RGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Crescent Biopharma (CBIO) has outperformed REGENXBIO (RGNX) over the past year, gaining 19.5% versus a loss of 27.7%. Over five years, RGNX leads with a -78.9% price change compared with -93.2% for CBIO. REGENXBIO is the larger company by market cap ($513.6 million vs $499.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CBIO | RGNX |
|---|---|---|
| Share price | $13.45 | $7.78 |
| Market cap | $499.62M | $513.58M |
| 1-day change | -0.30% | +2.44% |
| YTD return | +13.74% | -47.26% |
| 1-year return | +19.49% | -27.74% |
| 5-year return | -93.19% | -78.87% |
| EPS (TTM) | $-7.63 | $-3.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.41 | $16.19 |
| 52-week low | $8.72 | $5.46 |
| Distance from 52-week high | -50.93% | -51.95% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +134.20% | +203.08% |
| Average volume | 397.58K | 1.52M |
| Shares outstanding | 37.14M | 66.01M |
| Employees | 69 | 371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CBIO has outperformed RGNX by 47.2 percentage points over the past year.
About Crescent Biopharma
CBIO stock →Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About REGENXBIO
RGNX stock →REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 371 employees
CBIO vs RGNX FAQ
Which is bigger, Crescent Biopharma or REGENXBIO?
REGENXBIO (RGNX) is larger, with a market capitalization of $513.58M compared with $499.62M for Crescent Biopharma (CBIO).
Which stock has performed better over the past year, CBIO or RGNX?
CBIO returned +19.49% over the past 12 months, compared with -27.74% for RGNX (price return, excluding dividends). Past performance does not predict future results.
Are Crescent Biopharma and REGENXBIO in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Crescent Biopharma and Biotechnology: Biological Products (No Diagnostic Substances) for REGENXBIO.